DarwinHealth
Private Company
Total funding raised: $2M
Overview
DarwinHealth is a privately held, New York-based biotechnology company founded in 2015, operating at the intersection of diagnostics, drug discovery, and precision oncology. Its core intellectual property is a proprietary computational platform, leveraging systems biology and its 'Oncotecture' framework, to elucidate tumor master regulators and actionable checkpoints from patient data, thereby guiding therapeutic matching and novel target identification. The company pursues a dual business model: providing diagnostic services to match patients with therapies and leveraging its platform for internal drug discovery and pharmaceutical partnerships. DarwinHealth appears to be in an early commercial or pre-revenue stage, focusing on technology validation and partnership development.
Technology Platform
Proprietary systems biology and 'Oncotecture'-driven computational platform that uses algorithms to analyze gene regulatory networks, identify tumor master regulator proteins (checkpoints), and match them to effective drugs or drug combinations. It functions for both patient-specific diagnostic matching and de novo drug target discovery.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
DarwinHealth competes with large genomic profiling companies (e.g., Foundation Medicine, Tempus, Guardant Health) that also offer therapy matching, but differentiates by focusing on systems biology and master regulators beyond genetics. It also competes with other AI/ML-driven drug discovery platforms in oncology. Its defensibility lies in its specific Oncotecture methodology and strong academic foundation.